SLC5A2 and hydrops fetalis: These meta-analyses also showed evidence for areduced incidence of first HF hospitalization with SGLT2 inhibitors [38] andpersistent benefit in a subgroup of patients with stage 3–4 chronic kidneydisease and HFpEF [40].